Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

Regulatory Peptides

Volumn 146, Issue 1-3, 2008, Pages 243-249

  Sonne, David P ^a   Engstrøm, Thomas ^b   Treiman, Marek ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Cardioprotection; Infarction; Ischemia; Myocardial; Pharmacological; Postconditioning

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; EXENDIN 4; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIAL REPERFUSION INJURY; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; VENOMS;

RATTUS;

EID: 38149083367     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.10.001     Document Type: Article

References (36)

1. Bell G.I., Sanchez-Pescador R., Laybourn P.J., and Najarian R.C. Exon duplication and divergence in the human preproglucagon gene. Nature 304 (1983) 368-371
2. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49 (2006) 253-260
3. Rouille Y., Martin S., and Steiner D.F. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270 (1995) 26488-26496
4. Deacon C.F., Pridal L., Klarskov L., Olesen M., and Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 271 (1996) E458-E464
5. Knudsen L.B., and Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318 (1996) 429-435
6. Deacon C.F., Plamboeck A., Moller S., and Holst J.J. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 282 (2002) E873-E879
7. Basso C., and Thiene G. The pathophysiology of myocardial reperfusion: a pathologist's perspective. Heart 92 (2006) 1559-1562
8. Moens A.L., Claeys M.J., Timmermans J.P., and Vrints C.J. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 100 (2005) 179-190
9. Kloner R.A., and Rezkalla S.H. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovasc Res 70 (2006) 297-307
10. Argaud L., Gateau-Roesch O., Raisky O., Loufouat J., Robert D., and Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 111 (2005) 194-197
11. Hausenloy D.J., and Yellon D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12 (2007) 217-234
12. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., and Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005) 146-151
13. Bose A.K., Mocanu M.M., Carr R.D., and Yellon D.M. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19 (2005) 9-11
14. Bullock B.P., Heller R.S., and Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137 (1996) 2968-2978
15. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., and Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287 (2004) E1209-E1215
16. Vila Petroff M.G., Egan J.M., Wang X., and Sollott S.J. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 89 (2001) 445-452
17. Barragan J.M., Rodriguez R.E., and Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 266 (1994) E459-E466
18. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., Parker T.G., Huang Q., Drucker D.J., and Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144 (2003) 2242-2252
19. Nystrom T., Gonon A.T., Sjoholm A., and Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125 (2005) 173-177
20. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y.T., and Shannon R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110 (2004) 955-961
21. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., and Shannon R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962-965
22. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., and Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006) 694-699
23. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267 (1992) 7402-7405
24. Goke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., and Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268 (1993) 19650-19655
25. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., Ghatei M.A., and Bloom S.R. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281 (2001) E155-E161
26. Bose A.K., Mocanu M.M., Carr R.D., and Yellon D.M. Myocardial Ischaemia-reperõfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway. Cardiovasc Drugs Ther 21 (2007) 253-256
27. Wettergren A., Wojdemann M., and Holst J.J. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 19 (1998) 877-882
28. Nikolaidis L.A., Elahi D., Shen Y.T., and Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289 (2005) H2401-H2408
29. Amsterdam E.A., Hughes J.L., DeMaria A.N., Zelis R., and Mason D.T. Indirect assessment of myocardial oxygen consumption in the evaluation of mechanisms and therapy of angina pectoris. Am J Cardiol 33 (1974) 737-743
30. Fishbein M.C., Meerbaum S., Rit J., Lando U., Kanmatsuse K., Mercier J.C., Corday E., and Ganz W. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 101 (1981) 593-600
31. Yang H., Egan J.M., Wang Y., Moyes C.D., Roth J., Montrose M.H., and Montrose-Rafizadeh C. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 275 (1998) C675-C683
32. Ban K., Baggio L.L., Drucker D.J., and Husain M. Role of Glucagon-Like Peptide-1 in myocardial ischemia-reperfusion injury. Circulation 114 (2006) II-221
33. Vilsboll T., Agerso H., Krarup T., and Holst J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88 (2003) 220-224
34. Laskey W.K. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv 65 (2005) 361-367
35. Ma X., Zhang X., Li C., and Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol 19 (2006) 367-375
36. Staat P., Rioufol G., Piot C., Cottin Y., Cung T.T., L'Huillier I., Aupetit J.F., Bonnefoy E., Finet G., Andre-Fouet X., and Ovize M. Postconditioning the human heart. Circulation 112 (2005) 2143-2148